<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5815">
  <stage>Registered</stage>
  <submitdate>23/03/2016</submitdate>
  <approvaldate>23/03/2016</approvaldate>
  <nctid>NCT02732457</nctid>
  <trial_identification>
    <studytitle>Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients</studytitle>
    <scientifictitle>Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients</scientifictitle>
    <utrn />
    <trialacronym>HSCT-HIV</trialacronym>
    <secondaryid>IVPPHSCT01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV-1 Infection</healthcondition>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reduction in HIV-1 DNA levels in CD4+ T cells measured by real-time PCR - HIV-1 DNA in CD4+ T cells will be measured by real-time PCR and reported as HIV-1 DNA copies in 10e6 CD4+ T cells</outcome>
      <timepoint>3 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction in HIV-1 Antigens and Antibodies measured by ELISA and Western Blot - HIV-1 antigens and antibodies (Ag/Ab) in peripheral blood will be measured by 4th generation chemiluminescence microparticle immunoassay (CMIA) and by Western blot (WB).</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  HIV-1 infection, requiring allogeneic, haematopoietic SCT as determined by their
             treating Physician (Haematologist).

          -  Over 18 years of age

          -  Provision of written, informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  In the opinion of the investigator that the patient is not able to provide informed
             consent

          -  Hb &lt; 9 (g/dL)

          -  CD4+ T cell count &lt;100 (cells/Âµl)

          -  Serious coagulation abnormalities, platelet count &lt; 50.

          -  Patients currently taking medications that significantly affect the bleeding time
             (e.g. warfarine, clexane, FXa antagonists)

          -  History of allergy to local anaesthetics

          -  Pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/09/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>St Vincent's Hospital - Sydney</hospital>
    <postcode>2010 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Kirby Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the impact of allogeneic hematopoietic stem cell
      transplantations (HSCT) in HIV infected patients on the persistence of HIV and the HIV immune
      response.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02732457</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mark Polizzotto, MD</name>
      <address>St Vincent's Hospital, Sydney</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Mark Polizzotto, MD</name>
      <address />
      <phone>293850900</phone>
      <fax />
      <email>mpolizzotto@kirby.unsw.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>